vs
Ares Management Corp（ARES）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Ares Management Corp的季度营收约是Revvity的1.9倍（$1.5B vs $772.1M），Revvity净利率更高（12.7% vs 3.6%，领先9.1%），Ares Management Corp同比增速更快（19.5% vs 5.9%），过去两年Ares Management Corp的营收复合增速更高（45.9% vs 9.0%）
Ares Management Corp是一家全球知名的另类投资管理机构，业务覆盖信贷、私募股权及房地产三大投资领域。公司成立于1997年，在北美、欧洲、亚洲多地设有分支机构，为全球客户提供专业的另类资产管理服务。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ARES vs RVTY — 直观对比
营收规模更大
ARES
是对方的1.9倍
$772.1M
营收增速更快
ARES
高出13.7%
5.9%
净利率更高
RVTY
高出9.1%
3.6%
两年增速更快
ARES
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $772.1M |
| 净利润 | $54.2M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | 13.7% | 14.5% |
| 净利率 | 3.6% | 12.7% |
| 营收同比 | 19.5% | 5.9% |
| 净利润同比 | -69.4% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARESRVTY
| Q4 25 | $1.5B | $772.1M | ||
| Q3 25 | $1.7B | $698.9M | ||
| Q2 25 | $1.4B | $720.3M | ||
| Q1 25 | $1.1B | $664.8M | ||
| Q4 24 | $1.3B | $729.4M | ||
| Q3 24 | $1.1B | $684.0M | ||
| Q2 24 | $788.7M | $691.7M | ||
| Q1 24 | $707.4M | $649.9M |
净利润ARESRVTY
| Q4 25 | $54.2M | $98.4M | ||
| Q3 25 | $288.9M | $46.7M | ||
| Q2 25 | $137.1M | $53.9M | ||
| Q1 25 | $47.2M | $42.2M | ||
| Q4 24 | $177.3M | $94.6M | ||
| Q3 24 | $118.5M | $94.4M | ||
| Q2 24 | $94.9M | $55.4M | ||
| Q1 24 | $73.0M | $26.0M |
毛利率ARESRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率ARESRVTY
| Q4 25 | 13.7% | 14.5% | ||
| Q3 25 | 39.3% | 11.7% | ||
| Q2 25 | 21.3% | 12.6% | ||
| Q1 25 | 13.0% | 10.9% | ||
| Q4 24 | 31.8% | 16.3% | ||
| Q3 24 | 29.0% | 14.3% | ||
| Q2 24 | 40.2% | 12.4% | ||
| Q1 24 | 32.7% | 6.8% |
净利率ARESRVTY
| Q4 25 | 3.6% | 12.7% | ||
| Q3 25 | 17.4% | 6.7% | ||
| Q2 25 | 10.2% | 7.5% | ||
| Q1 25 | 4.3% | 6.4% | ||
| Q4 24 | 14.1% | 13.0% | ||
| Q3 24 | 10.5% | 13.8% | ||
| Q2 24 | 12.0% | 8.0% | ||
| Q1 24 | 10.3% | 4.0% |
每股收益（稀释后）ARESRVTY
| Q4 25 | — | $0.86 | ||
| Q3 25 | — | $0.40 | ||
| Q2 25 | — | $0.46 | ||
| Q1 25 | — | $0.35 | ||
| Q4 24 | — | $0.77 | ||
| Q3 24 | — | $0.77 | ||
| Q2 24 | — | $0.45 | ||
| Q1 24 | — | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.3B | $7.3B |
| 总资产 | $28.6B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARESRVTY
| Q4 25 | — | $919.9M | ||
| Q3 25 | — | $931.4M | ||
| Q2 25 | — | $991.8M | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $2.0B | ||
| Q1 24 | — | $1.7B |
股东权益ARESRVTY
| Q4 25 | $4.3B | $7.3B | ||
| Q3 25 | $4.5B | $7.4B | ||
| Q2 25 | $4.4B | $7.6B | ||
| Q1 25 | $4.5B | $7.6B | ||
| Q4 24 | $3.5B | $7.7B | ||
| Q3 24 | $2.1B | $7.9B | ||
| Q2 24 | $2.0B | $7.9B | ||
| Q1 24 | $1.8B | $7.8B |
总资产ARESRVTY
| Q4 25 | $28.6B | $12.2B | ||
| Q3 25 | $27.0B | $12.1B | ||
| Q2 25 | $27.3B | $12.4B | ||
| Q1 25 | $27.2B | $12.4B | ||
| Q4 24 | $24.9B | $12.4B | ||
| Q3 24 | $24.5B | $12.8B | ||
| Q2 24 | $24.2B | $13.4B | ||
| Q1 24 | $24.4B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-483.7M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | -8.92× | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流ARESRVTY
| Q4 25 | $-483.7M | $182.0M | ||
| Q3 25 | $1.3B | $138.5M | ||
| Q2 25 | $415.7M | $134.3M | ||
| Q1 25 | $2.0B | $128.2M | ||
| Q4 24 | $807.6M | $174.2M | ||
| Q3 24 | $841.3M | $147.9M | ||
| Q2 24 | $432.2M | $158.6M | ||
| Q1 24 | $710.0M | $147.6M |
自由现金流ARESRVTY
| Q4 25 | — | $161.8M | ||
| Q3 25 | — | $120.0M | ||
| Q2 25 | — | $115.5M | ||
| Q1 25 | — | $112.2M | ||
| Q4 24 | — | $149.8M | ||
| Q3 24 | — | $125.6M | ||
| Q2 24 | — | $136.6M | ||
| Q1 24 | — | $129.7M |
自由现金流率ARESRVTY
| Q4 25 | — | 21.0% | ||
| Q3 25 | — | 17.2% | ||
| Q2 25 | — | 16.0% | ||
| Q1 25 | — | 16.9% | ||
| Q4 24 | — | 20.5% | ||
| Q3 24 | — | 18.4% | ||
| Q2 24 | — | 19.7% | ||
| Q1 24 | — | 20.0% |
资本支出强度ARESRVTY
| Q4 25 | — | 2.6% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | — | 2.6% | ||
| Q1 25 | — | 2.4% | ||
| Q4 24 | — | 3.4% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 3.2% | ||
| Q1 24 | — | 2.7% |
现金转化率ARESRVTY
| Q4 25 | -8.92× | 1.85× | ||
| Q3 25 | 4.64× | 2.97× | ||
| Q2 25 | 3.03× | 2.49× | ||
| Q1 25 | 42.28× | 3.03× | ||
| Q4 24 | 4.55× | 1.84× | ||
| Q3 24 | 7.10× | 1.57× | ||
| Q2 24 | 4.55× | 2.87× | ||
| Q1 24 | 9.72× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ARES
| Management Service | $991.1M | 66% |
| Management Service Incentive | $206.7M | 14% |
| Carried Interest | $205.4M | 14% |
| Fee Related Performance Revenues | $113.3M | 8% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
